A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors.
Yong FangFan MoJiawei ShouHuimin WangKai LuoShanshan ZhangNing HanHongsen LiShengli YeZhan ZhouRongchang ChenLiang LiuHuina WangHongming PanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
iNeo-Vac-P01 as monotherapy is feasible and safe for patients with advanced solid tumors. It could elicit T-cell-mediated immune response targeting tumor neoantigens, and might have promising antitumor efficacy.See related commentary by Filderman and Storkus, p. 4429.